A Phase I Study of SR-4554 via Intravenous Administration for Noninvasive Investigation of Tumor Hypoxia by Magnetic Resonance Spectroscopy in Patients with Malignancy

Clinical Cancer Research

Volumn 9, Issue 14, 2003, Pages 5101-5112

  Seddon, Beatrice M ^a   Payne, Geoffrey S ^a   Simmons, Laura ^a   Ruddle, Ruth ^a   Grimshaw, Rachel ^a   Tan, Siew ^a   Turner, Alison ^c   Raynaud, Florence ^a   Halbert, Gavin ^d   Leach, Martin O ^a,b   Judson, Ian ^a,b   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOXIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUORINE RADIOISOTOPES; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; NITROIMIDAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 10744220055     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Dische, S. Chemical sensitisers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother. Oncol., 3: 97-115, 1985.
2. Overgaard, J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res., 6: 509-518, 1994.
3. Hodgkiss, R. J. Use of 2-nitroimidazoles as bioreductive markers for tumor hypoxia. Anticancer Drug Des., 13: 687-702, 1998.
4. Kennedy, A. S., Raleigh, J. A., Perez, G. M., Calkins, D. P., Thrall, D. E., Novotny. D. B., and Varia, M. A. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int. J. Radiat. Oncol. Biol. Phys., 37: 897-905, 1997.
5. Nordsmark, M., Loncaster, J., Chou, S. J., Havsteen, H., Lindegaard, J. C., Davidson, S. E., Varia, M. A., West, C., Hunter, R., Overgaard, J., and Raleigh, J. A. Invasive oxygen measurements and pimonidazole labelling in human cervix carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 49: 581-586, 2001.
6. Raleigh, J. A., Calkins-Adams, D. P., Rinker, L. H., Ballenger, C. A., Weissler, M. C., Fowler, W. C., Novotny, D. B., and Varia, M. A. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxic marker. Cancer Res., 58: 3765-3768, 1998.
7. Varia, M. A., Calkins-Adams, D. P., Rinker, L. H., Kennedy, A. S., Novotny, D. B., Fowler, W. C., and Raleigh, J. A. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynaecol. Oncol., 71: 270-277, 1998.
8. Evans, S. M., Hahn, S. M., Magarelli, D. P., Zhang, P. J., Jenkins, W. T., Fraker, D. L., Hsi, R. A., McKenna, W. G., and Koch, C. J. Hypoxia in human intraperitoneal and extremity sarcomas. Int. J. Radiat. Oncol. Biol. Phys., 49: 587-596, 2001.
9. Evans, S. M., Hahn, S. M., Magarelli, D. P., and Koch, C. J. Hypoxic heterogeneity in human tumors. Am. J. Clin. Oncol., 24: 467-472, 2001.
10. Aboagye, E. O., Lewis, A. D., Johnson, A., Workman, P., Tracy, M., and Huxham, I. M. The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semi-quantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. Br. J. Cancer, 72: 312-318, 1995.
11. Aboagye, E. O., Kelson, A. B., Tracy, M., and Workman, P. Preclinical development and current status of the fluorinated 2-nitro-imidazole hypoxia probe N-(2-hydroxy-3, 3, 3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anticancer Drug Des., 13: 703-730, 1998.
12. Aboagye, E. O., Maxwell, R. J., Kelson, A. B., Tracy, M., Lewis, A. D., Graham, M. A., Horsman, M. R., Griffiths, J. R., and Workman, P. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3, 3, 3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia. Cancer Res., 57: 3314-3318, 1997.
13. Aboagye, E. O., Lewis, A. D., Tracy, M., and Workman, P. Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3, 3, 3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554). Biochem. Pharmacol., 54: 1217-1224, 1997.
14. Aboagye, E. O., Maxwell, R. J., Horsman, M. R., Lewis, A. D., Workman, P., Tracy, M., and Griffiths, J. R. The relationship between tumor oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554. Br. J. Cancer, 77: 65-70, 1998.
15. Seddon, B. M., Maxwell, R. J., Honess, D. J., Grimshaw, R., Raynaud, F., Tozer, G. M., and Workman, P. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin. Cancer. Res., 8: 2323-2335, 2002.
16. Aboagye, E. O., Lewis, A. D., Graham, M. A., Tracey, M., Kelson, A. B., and Workman, P. The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554. Anticancer Drug Des., 11: 231-242, 1996.
17. Schlemmer, H-P., Becker, M., Bachert, P., Dietz, A., Rudat, V., Vanselow, B., Wollensack, P., Zuna, I., Knopp, M. V., Weidauer, M., and van Kaick, G. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res., 59: 2363-2369, 1999.
18. 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed., 11: 380-387, 1998.
19. 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann. Oncol., 4: 597-602, 1993.
20. Ikehira, H., Girard. F., Obata, T., Ito, H., Yoshitomi, H., Miyazaki, M., Nakajima, N., Kamei, H., Kanazawa, Y., Takano, H., Ito, H., Tanada, S., and Sasaki, Y. A preliminary study for clinical pharmacokinetics of oral fluorine anticancer medicines using the commercial MRI system 19F-MRS. Br. J. Radiol., 72: 584-589, 1999.
21. Coleman, C. N., Urtasun, R. C., Wasserman, T. H., Hancock, S., Harris, J. W., Halsey, J., and Hirst, V. K. Initial report of the phase I trial of the hypoxic cell radiosensitiser SR-2508. Int. J. Radiat. Oncol. Biol. Phys., 10: 1749-1753, 1984.
22. Coleman, C. N., Wasserman, T. H., Urtasun, R. C., Halsey, J., Hirst, V. K., Hancock, S., and Phillips, T. L. Phase I trial of the hypoxic cell radiosensitiser SR-2508: the results of the five to six week drug schedule. Int. J. Radiat. Oncol. Biol. Phys., 12: 1105-1108, 1986.
23. Koch, C. J., Hahn, S. M., Rockwell, K., Jr., Covey, J. M., McKenna, W. G., and Evans, S. M. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazobl-1-yl)-N-(2, 2, 3, 3, 3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother. Pharmacol., 48: 177-187, 2001.
24. Newman, H. F., Bleehen, N. M., and Workman, P. A phase I study of the combination of two hypoxic cell radiosensitisers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics. Int. J. Radiat. Oncol. Biol. Phys., 12: 1113-1116, 1986.
25. Shibamoto, Y., Takahashi, M., and Abe, M. A phase I study of KU-2285 in combination with conventional radiotherapy. Radiother. Oncol., 40: 55-58, 1996.
26. Shibamoto, Y., Ohshio, G., Hosotani, R., Nishimura, Y., Manabe, T., Imamura, M., and Abe, M. A phase I/II study of a hypoxic cell radiosensitiser KU-2285 in combination with intraoperative radiotherapy. Br. J. Cancer, 76: 1474-1479, 1997.
27. Urtasun, R. C., Chapman, J. D., Band, P., Rabin, H. R., Fryer, C. G., and Sturmwind, J. Phase I study of high-dose metronidazole: a specific in vivo and in vitro radiosensitiser of hypoxic cells. Radiology, 117: 129-133, 1975.
28. Thomas, G. M., Rauth, A. M., Bush, R. S., Black, B. E., and Cummings, B. J. A toxicity study of daily metronidazole with pelvic irradiation. Cancer Clin. Trials, 3: 223-230, 1980.
29. Overgaard, J., Overgaard, M., and Timothy, A. R. Studies of the pharmacokinetic properties of nimorazole. Br. J. Cancer, 48: 27-34, 1983.
30. Okkan, S., Yazici, Z., Uzel, R., Akçasu, A., Turkan, S., Hacibekiroglu, M., Olgun, P., and Egehan, I. Use of ornidazole in fractionated radiotherapy: dose tolerance, serum and tumor tissue concentration. Radiother. Oncol., 5: 295-301, 1986.
31. Dische, S., Saunders, M. I., Flockhart, I. R., Lee, M. E., and Anderson, P. Misonidazole - a drug for trial in radiotherapy and oncology. Int. J. Radiat. Oncol. Biol. Phys., 5: 851-860, 1979.
32. Wasserman, T. H., Phillips, T. L., Johnson, R. J., Gomer, C. J., Lawrence, G. A., Sadee, W., Marques, R. A., Levin, V. A., and Van Raalte, G. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), a hypoxic cell radiosensitiser. Int. J. Radiat. Oncol. Biol. Phys., 5: 775-786, 1979.
33. Workman, P., Wiltshire, C. R., Plowman, P. N., and Bleehen, N. M. Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br. J. Cancer, 38: 709-718, 1978.
34. Coleman, C. N., Wasserman, T. H., Phillips, T. L., Strong, J. M., Urtasun, R. C., Schwade, J. G., Johnson, R. J., and Zagars, G. Initial pharmacology and toxicology of intravenous desmethylmisonidazole. Int. J. Radiat. Oncol. Biol. Phys., 8: 371-375, 1982.
35. Roberts, J. T., Bleehen, N. M., Walton, M. I., and Workman, P. A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumor and normal brain pharmacokinetics. Br. J. Radiol., 59: 107-116, 1986.
36. Oya, N., Shibamoto, Y., Sasai, K., Shibata, T., Murata, T., Takagi, T., Iwai, H., Suzuki, T., and Abe, M. Optical isomers of a new 2-nitroimidazole nucleoside analogue (PR-350 series): radiosensitisation efficiency and toxicity. Int. J. Radiat. Oncol. Biol. Phys., 33: 119-127, 1995.
37. Nemoto, K., Shibamoto, Y., Ohmagari, J., Baba, Y., Ebe, K., Ariga, H., Takai, Y., Ouchi, A., Sasai, K., Shinozaki, M., Tsujitani, M., Sakaguchi, M., Yamada, S., and Sakamoto, K. Phase 1a study of a hypoxic cell sensitiser doranidazole (PR-350) in combination with conventional radiotherapy. Anticancer Drugs, 12: 1-6, 2001.
38. Brown, J. M., and Workman. P. Partition coefficient as a guide to the development of radiosensitisers which are less toxic than misonidazole. Radiat. Res., 82: 171-190, 1980.
39. White, R. A. S., Workman, P., and Brown, J. M. The pharmacokinetics and tumor and neural tissue penetrating properties of SR 2508 and SR 2555 in the dog-hydrophilic radiosensitisers potentially less toxic than misonidazole. Radiat. Res., 84: 542-561, 1980.
40. Workman, P., and Brown, J. M. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother. Pharmacol., 6: 39-49, 1981.
41. Cottrill, C., Bishop, K., Walton, M. I., and Henk, J. M. Pilot study of nimorazole as a hypoxic-cell sensitiser with the 'CHART' regime in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 42: 807-810, 1998.
42. Overgaard, J. Randomised double-blind phase III study of nimorazole as a hypoxic radiosensitiser of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother. Oncol., 46: 135-146, 1998.
43. Timothy, A. R., Overgaard, J., and Overgaard, M. A phase I clinical study of nimorazole as a hypoxic radiosensitiser. Int. J. Radiat. Oncol. Biol. Phys., 10: 1765-1768, 1984.
44. Gray, A. J., Dische, S., Adams, G. E., Flockhart, I. R., and Foster, J. L. Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumor concentrations. Clin. Radiol., 27: 151-157, 1976.
45. Urtasun, R. C., Band, P., Chapman, J. D., Rabin, H. R., Wilson, A. F., and Fryer, C. G. Clinical phase I study of the hypoxic cell radiosensitiser Ro-07-0582, a 2-nitroimidazole derivative. Radiology, 122: 801-804, 1977.